Pfizer · NSE: PFIZER · BSE: 500680
Q2 FY25 results · Jul–Sep 2024
Pfizer reported revenue from operations of ₹588.59 crore (up 2.3% from Q2 FY24) and net profit of ₹158.35 crore (up 6.3% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a standalone basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 588.59 | 575.21 | +2.3% | 562.86 | +4.6% |
| Other income | 43.07 | 36.07 | +19.4% | 41.84 | +2.9% |
| Total income | 631.66 | 611.28 | +3.3% | 604.70 | +4.5% |
| Profit before tax | 215.23 | 200.52 | +7.3% | 202.62 | +6.2% |
| Net profit for the period | 158.35 | 148.96 | +6.3% | 150.71 | +5.1% |
| EPS, basic (₹) | 34.61 | 32.56 | +6.3% | 32.94 | +5.1% |
| Net margin (%) | 26.9 | 25.9 | 26.8 |
Standalone
- Filed with BSE
- 28 Oct 2024, 19:52 IST
- Board meeting
- 28 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE